SCHEMBL688787

SCHEMBL688787

CC1(C)CC(=O)CC(C)(C)[N]1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14016355 0.69 SMN1; SMN2 (0.38) MAPT
SCHEMBL2691041 0.69
SCHEMBL4859696 0.69 KDM4E (0.39) MAPT
SCHEMBL2706623 0.69 SMN1; SMN2 (0.38) MAPT
SCHEMBL24535432 0.69
SCHEMBL6234255 0.69
SCHEMBL50791 0.67 GAA (0.39)
SCHEMBL15200349 0.67
SCHEMBL24535427 0.65
SCHEMBL24535421 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855726-B1 Quinolones as serine protease inhibitors WARNER-LAMBERT COMPANY LLC (US) 2005-02-15 US claimed
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors BERRYMAN KENT ALAN (US) 2003-10-02 US claimed
US-6509335-B1 This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of WARNER-LAMBERT COMPANY 2003-01-21 US claimed
US-20020086866-A1 Quinoxalinones as serine protease inhibitors DUDLEY DANETTE ANDREA (US) 2002-07-04 US claimed
US-6410536-B1 ANTICOAGULANTS WARNER-LAMBERT COMPANY 2002-06-25 US claimed
EP-1091955-A1 QUINOLONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2001-04-18 EP claimed
EP-1068191-A1 BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2001-01-17 EP claimed
EP-1068190-A1 QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN WARNER-LAMBERT COMPANY LLC (US) 2001-01-17 EP claimed
WO-1999050254-A1 QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN WARNER-LAMBERT COMPANY (US) 1999-10-07 WO claimed
WO-1999050257-A1 BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-10-07 WO claimed
WO-1999050263-A1 QUINOLONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-10-07 WO claimed
US-5698683-A Mixed aluminium-heavy metal dyestuff complexes and a process for their preparation CLARIANT FINANCE (BVI) LIMITED (BG) 1997-12-16 US claimed
US-11021585-B2 Light stabilized polyolefin films, tapes and monofilaments BASF SE (DE) 2021-06-01 US disclosed
US-20200223996-A1 LIGHT STABILIZED POLYOLEFIN FILMS, TAPES AND MONOFILAMENTS BASF SE (DE) 2020-07-16 US disclosed
US-10689495-B2 Light stabilized polyolefin films, tapes and monofilaments BASF SE (DE) 2020-06-23 US disclosed
EP-3473670-B1 LIGHT STABILIZED POLYOLEFIN FILMS, TAPES AND MONOFILAMENTS BASF SE (DE) 2020-04-15 EP disclosed
US-5719217-A COMPRISING AT LEAST TWO DIFFERENT POLYMERIC POLYALKYLPIPERIDINE DERIVATIVES CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-02-17 US disclosed
US-5698683-A Mixed aluminium-heavy metal dyestuff complexes and a process for their preparation CLARIANT FINANCE (BVI) LIMITED (BG) 1997-12-16 US disclosed
US-4863981-A POLYMERS CONTAINING POLYALKYLPIPERDINE GROUPS CIBA-GEIGY CORPORATION (US) 1989-09-05 US disclosed
US-4168981-A Bis(substituted amino)sulfides as reversible inhibitor sources for photopolymerization E. I. DU PONT DE NEMOURS AND COMPANY (US) 1979-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086866-A1 Quinoxalinones as serine protease inhibitors HABP2, SERPINB1, PRSS1 ALDH1A1 1960/4885POLB 4509/4885MAPT 4000/4885
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors HABP2, SPINT2, SERPINB1 ALDH1A1 2444/4885POLB 4517/4885MAPT 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.